查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1590887

HPV 相關疾病市場：依適應症、治療方法、分佈分類 - 2025-2030 年全球預測

HPV Associated Disorders Market by Indication (AIN, Anal Cancer, Cervical Cancer), Therapy (Prevention, Treatment), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年HPV相關疾病市場價值為93億美元，預計2024年將達到98.4億美元，複合年成長率為6.13%，預計2030年將達到141.1億美元。

HPV相關疾病市場包括人類乳突病毒（HPV）引起的疾病的診斷、治療和預防，例如子宮頸癌、口咽癌、肛門癌和尖銳濕疣。全球 HPV 感染的高盛行率及其與癌症和非癌症疾病的關聯凸顯了對該市場的需求，這需要強力的篩檢計劃、疫苗和治療方法。最終使用者是醫療保健提供者、醫院、研究機構和尋求預防和治療解決方案的個別患者。關鍵的成長要素包括人們對 HPV 相關健康風險的認知提高、疫苗接種計劃的擴大、分子診斷技術的進步以及政府和機構對預防措施的大力支持。最新的機會在於人類乳突病毒(HPV)疫苗的廣泛使用、更有效的診斷方法的開發以及新興經濟體醫療保健支出的增加。公司可以透過投資下一代疫苗研發、個人化醫療方法以及改善全球 HPV 相關醫療保健資源的獲取來抓住這些機會。然而，市場成長受到諸如低收入地區的財務限制、疫苗接種猶豫不決、有關 HPV 及其疫苗的錯誤訊息以及獲得疫苗和醫療保健方面的差異等限制因素的阻礙。挑戰還包括監管障礙以及提高篩檢和診斷準確性的持續需求。需要創新的領域包括提高疫苗功效和交付、開發照護現場診斷測試以及利用人工智慧來預測和管理 HPV 相關疾病的進展。對市場特徵的回顧凸顯了技術突破頻繁的競爭格局，早期採用創新和策略聯盟對於持續成長至關重要。對於公司來說，擴大市場覆蓋範圍和影響力的建議策略是與政府和非政府衛生組織建立合作夥伴關係，並專注於反虛假資訊的教育宣傳活動。

主要市場統計
基準年[2023] 93億美元
預測年份 [2024] 98.4億美元
預測年份 [2030] 141.1億美元
複合年成長率（%） 6.13%

市場動態：針對快速發展的 HPV 相關疾病市場揭示的關鍵市場見解

供需的動態交互作用正在改變 HPV 相關疾病市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • HPV 相關疾病的盛行率上升
    • 標靶治療的生長發育
    • 政府積極支持並舉措提高 HPV感染疾病意識
  • 市場限制因素
    • 與 HPV 相關的副作用
  • 市場機會
    • 增加癌症研究的經費和投資
    • HPV 聯合檢測技術不斷進步
  • 市場挑戰
    • 患者缺乏對多種治療方案的認知

波特五力：開拓 HPV 相關疾病市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 HPV 相關疾病市場的外部影響

外部宏觀環境因素在塑造 HPV 相關疾病市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解 HPV 相關疾病市場的競爭格局

對 HPV 相關疾病市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣供應商在 HPV 相關疾病市場的績效評估

FPNV定位矩陣是評估HPV相關疾病市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了 HPV 相關疾病市場的成功之路

HPV 相關疾病市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • HPV 相關疾病的發生率增加
      • 標靶治療的生長發育
      • 政府積極支持並努力提高人們對 HPV 疾病的認知
    • 抑制因素
      • 與 HPV 相關的副作用
    • 機會
      • 增加癌症研究的經費和投資
      • 同步 HPV 檢測的技術進步
    • 任務
      • 患者缺乏對多種治療方案的認知
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 HPV相關疾病市場（依適應症）

  • 艾因
  • 肛門癌
  • 子宮頸癌
  • 脛
  • 尖圭濕疣

第7章 HPV相關疾病市場治療

  • 預防
  • 治療

第8章 HPV相關疾病市場經銷商

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章 美洲HPV相關疾病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區HPV相關疾病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲HPV相關疾病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alembic Pharmaceuticals
  • AstraZeneca plc
  • Bausch Health Companies Inc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company.
  • F. Hoffmann-La Roche Ltd
  • GEA Group Aktiengesellschaft
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • JM Huber Corporation
  • Johnson & Johnson Services, Inc.
  • KinoPharma, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
Product Code: MRR-ED54C46E9175

The HPV Associated Disorders Market was valued at USD 9.30 billion in 2023, expected to reach USD 9.84 billion in 2024, and is projected to grow at a CAGR of 6.13%, to USD 14.11 billion by 2030.

The HPV associated disorders market encompasses the diagnosis, treatment, and prevention of diseases caused by the human papillomavirus (HPV), including cervical, oropharyngeal, and anal cancers, as well as genital warts. The necessity of this market is underscored by the high prevalence of HPV infections worldwide and their association with cancerous and non-cancerous conditions, necessitating robust screening programs, vaccines, and therapeutics. The application extends to healthcare providers, hospitals, and research institutions, while the end-use scope covers individual patients seeking preventative and therapeutic solutions. Key growth factors include increasing awareness about HPV-related health risks, expanding vaccination programs, technological advancements in molecular diagnostics, and strong government and organizational support for preventative measures. The latest opportunities lie in the exploitation of HPV vaccines' rising acceptance, ongoing development of more efficient diagnostic methods, and increased healthcare spending in emerging economies. Companies could seize these opportunities by investing in R&D for next-generation vaccines, personalized medicine approaches, and improving access to HPV-related healthcare resources globally. Nonetheless, market growth is hampered by limitations such as financial constraints in low-income regions, vaccine hesitancy, misinformation about HPV and its vaccines, and disparities in vaccine and healthcare access. Challenging factors also include regulatory hurdles and the ongoing need to enhance screening and diagnostic accuracy. Areas ripe for innovation include enhancing the efficacy and delivery of vaccines, developing point-of-care diagnostic tests, and leveraging artificial intelligence to predict and manage HPV-associated disease progression. Insights into the market's nature highlight a competitive landscape with frequent technological breakthroughs, making early adoption of innovations and strategic partnerships crucial for sustained growth. For businesses, fostering collaborations with governmental and non-governmental health organizations and focusing on educational campaigns to combat misinformation are recommended strategies to widen market reach and impact.

KEY MARKET STATISTICS
Base Year [2023] USD 9.30 billion
Estimated Year [2024] USD 9.84 billion
Forecast Year [2030] USD 14.11 billion
CAGR (%) 6.13%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HPV Associated Disorders Market

The HPV Associated Disorders Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of HPV related diseases
    • Growth and development in targeted therapies
    • Proactive government support and initiatives for HPV disorders awareness
  • Market Restraints
    • Adverse effects associated with HPV
  • Market Opportunities
    • Increased funding and investment for cancer research
    • Growing technological advancement in HPV co-testing
  • Market Challenges
    • Lack of patient awareness regarding several treatments options

Porter's Five Forces: A Strategic Tool for Navigating the HPV Associated Disorders Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HPV Associated Disorders Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HPV Associated Disorders Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HPV Associated Disorders Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HPV Associated Disorders Market

A detailed market share analysis in the HPV Associated Disorders Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HPV Associated Disorders Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HPV Associated Disorders Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the HPV Associated Disorders Market

A strategic analysis of the HPV Associated Disorders Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the HPV Associated Disorders Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals, AstraZeneca plc, Bausch Health Companies Inc, Biocon Ltd., Bristol-Myers Squibb Co., Eli Lilly and Company., F. Hoffmann-La Roche Ltd, GEA Group Aktiengesellschaft, GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., J.M. Huber Corporation, Johnson & Johnson Services, Inc., KinoPharma, Inc., Merck & Co., Inc., Novartis AG, and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the HPV Associated Disorders Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across AIN, Anal Cancer, Cervical Cancer, CIN, and Genital Warts.
  • Based on Therapy, market is studied across Prevention and Treatment.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of HPV related diseases
      • 5.1.1.2. Growth and development in targeted therapies
      • 5.1.1.3. Proactive government support and initiatives for HPV disorders awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects associated with HPV
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased funding and investment for cancer research
      • 5.1.3.2. Growing technological advancement in HPV co-testing
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of patient awareness regarding several treatments options
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. HPV Associated Disorders Market, by Indication

  • 6.1. Introduction
  • 6.2. AIN
  • 6.3. Anal Cancer
  • 6.4. Cervical Cancer
  • 6.5. CIN
  • 6.6. Genital Warts

7. HPV Associated Disorders Market, by Therapy

  • 7.1. Introduction
  • 7.2. Prevention
  • 7.3. Treatment

8. HPV Associated Disorders Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas HPV Associated Disorders Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific HPV Associated Disorders Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa HPV Associated Disorders Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals
  • 2. AstraZeneca plc
  • 3. Bausch Health Companies Inc
  • 4. Biocon Ltd.
  • 5. Bristol-Myers Squibb Co.
  • 6. Eli Lilly and Company.
  • 7. F. Hoffmann-La Roche Ltd
  • 8. GEA Group Aktiengesellschaft
  • 9. GlaxoSmithKline plc
  • 10. Inovio Pharmaceuticals, Inc.
  • 11. J.M. Huber Corporation
  • 12. Johnson & Johnson Services, Inc.
  • 13. KinoPharma, Inc.
  • 14. Merck & Co., Inc.
  • 15. Novartis AG
  • 16. Pfizer, Inc.

LIST OF FIGURES

  • FIGURE 1. HPV ASSOCIATED DISORDERS MARKET RESEARCH PROCESS
  • FIGURE 2. HPV ASSOCIATED DISORDERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HPV ASSOCIATED DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HPV ASSOCIATED DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HPV ASSOCIATED DISORDERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HPV ASSOCIATED DISORDERS MARKET DYNAMICS
  • TABLE 7. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY AIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY ANAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. HPV ASSOCIATED DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. HPV ASSOCIATED DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023